122 related articles for article (PubMed ID: 38315961)
1. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
Varey AHR; Li I; El Sharouni MA; Simon J; Dedeilia A; Ch'ng S; Saw RPM; Spillane AJ; Shannon KF; Pennington TE; Rtshiladze M; Stretch JR; Nieweg OE; van Akkooi A; Sullivan RJ; Boland GM; Gershenwald JE; van Diest PJ; Scolyer RA; Long GV; Thompson JF; Lo SN
J Clin Oncol; 2024 Apr; 42(10):1169-1180. PubMed ID: 38315961
[TBL] [Abstract][Full Text] [Related]
2. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
3. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.
El Sharouni MA; Stodell MD; Ahmed T; Suijkerbuijk KPM; Cust AE; Witkamp AJ; Sigurdsson V; van Diest PJ; Scolyer RA; Thompson JF; van Gils CH; Lo SN
Ann Oncol; 2021 Mar; 32(3):375-383. PubMed ID: 33253862
[TBL] [Abstract][Full Text] [Related]
4. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
6. External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program.
Tjokrowidjaja A; Browne L; Soudy H
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e280-e288. PubMed ID: 34811927
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
Moncrieff MD; Lo SN; Scolyer RA; Heaton MJ; Nobes JP; Snelling AP; Carr MJ; Nessim C; Wade R; Peach AH; Kisyova R; Mason J; Wilson ED; Nolan G; Pritchard Jones R; Johansson I; Olofsson Bagge R; Wright LJ; Patel NG; Sondak VK; Thompson JF; Zager JS
J Clin Oncol; 2022 Dec; 40(34):3940-3951. PubMed ID: 35849790
[TBL] [Abstract][Full Text] [Related]
8. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.
Bajaj S; Donnelly D; Call M; Johannet P; Moran U; Polsky D; Shapiro R; Berman R; Pavlick A; Weber J; Zhong J; Osman I
J Natl Cancer Inst; 2020 Sep; 112(9):921-928. PubMed ID: 31977051
[TBL] [Abstract][Full Text] [Related]
9. External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?
Madu MF; Franke V; Van de Wiel BA; Klop WMC; Jóźwiak K; van Houdt WJ; Wouters MWJM; van Akkooi ACJ
Melanoma Res; 2020 Apr; 30(2):185-192. PubMed ID: 31651715
[TBL] [Abstract][Full Text] [Related]
10. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
11. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E
Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470
[TBL] [Abstract][Full Text] [Related]
12. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
Fujisawa Y; Yoshikawa S; Minagawa A; Takenouchi T; Yokota K; Uchi H; Noma N; Nakamura Y; Asai J; Kato J; Fujiwara S; Fukushima S; Uehara J; Hoashi T; Kaji T; Fujimura T; Namikawa K; Yoshioka M; Murata N; Ogata D; Matsuyama K; Hatta N; Shibayama Y; Fujiyama T; Ishikawa M; Yamada D; Kishi A; Nakamura Y; Shimiauchi T; Fujii K; Fujimoto M; Ihn H; Katoh N
J Dermatol Sci; 2019 May; 94(2):284-289. PubMed ID: 31023613
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Larkin J; Weber J; Del Vecchio M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; De la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Mandalá M
Eur J Cancer; 2022 Sep; 173():285-296. PubMed ID: 35964471
[TBL] [Abstract][Full Text] [Related]
14. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
[TBL] [Abstract][Full Text] [Related]
15. Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort.
El Sharouni MA; Varey AHR; Witkamp AJ; Ahmed T; Sigurdsson V; van Diest PJ; Scolyer RA; Thompson JF; Lo SN; van Gils CH
Br J Dermatol; 2021 Aug; 185(2):412-418. PubMed ID: 33657653
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
17. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
18. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model.
Callender GG; Gershenwald JE; Egger ME; Scoggins CR; Martin RC; Schacherer CW; Edwards MJ; Urist MM; Ross MI; Stromberg AJ; McMasters KM
J Am Coll Surg; 2012 Apr; 214(4):608-17; discussion 617-9. PubMed ID: 22342785
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
[TBL] [Abstract][Full Text] [Related]
20. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
